Literature DB >> 10871393

RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts.

M Scherr1, J J Rossi, G Sczakiel, V Patzel.   

Abstract

The use of antisense oligodeoxyribonucleotides (ODN) or ribozymes to specifically suppress gene expression is simple in concept and relies on efficient binding of the antisense strand to the target RNA. Although the identification of target sites accessible to base pairing is gradually being overcome by different techniques, it remains a major problem in the antisense and ribozyme approaches. In this study we have investigated the potential of a recent experimental and theoretical approach to predict the local accessibility of murine DNA-methyltransferase (MTase) mRNA in a comparative way. The accessibility of the native target RNA was probed with antisense ODN in cellular extracts. The results strongly correlated with the theoretically predicted target accessibility. This work suggests an effective two-step procedure for predicting RNA accessibility: first, computer-aided selection of ODN binding sites defined by an accessibility score followed by a more detailed experimental procedure to derive information about target accessibility at the single nucleotide level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871393      PMCID: PMC102709          DOI: 10.1093/nar/28.13.2455

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  23 in total

1.  Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library.

Authors:  A Lieber; M Strauss
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

2.  Protein enhancement of hammerhead ribozyme catalysis.

Authors:  Z Tsuchihashi; M Khosla; D Herschlag
Journal:  Science       Date:  1993-10-01       Impact factor: 47.728

3.  Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts.

Authors:  M Scherr; J J Rossi
Journal:  Nucleic Acids Res       Date:  1998-11-15       Impact factor: 16.971

4.  Kinetics of renaturation of DNA.

Authors:  J G Wetmur; N Davidson
Journal:  J Mol Biol       Date:  1968-02-14       Impact factor: 5.469

5.  Design of hammerhead ribozymes for the inhibition of gene expression ex vivo by exogenous application.

Authors:  F Eckstein; H Aurup; F Benseler; O Heidenreich; P Marschall; M Ng; J Thomson; T Tuschl
Journal:  Nucleic Acids Symp Ser       Date:  1993

Review 6.  Gene inhibition using antisense oligodeoxynucleotides.

Authors:  R W Wagner
Journal:  Nature       Date:  1994-11-24       Impact factor: 49.962

7.  Kinetics of Renaturation of Denatured DNA. I. Spectrophotometric results.

Authors:  J A Subirana; P Doty
Journal:  Biopolymers       Date:  1966       Impact factor: 2.505

Review 8.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

Authors:  C A Stein; Y C Cheng
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

9.  Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1.

Authors:  A Peyman; M Helsberg; G Kretzschmar; M Mag; S Grabley; E Uhlmann
Journal:  Biol Chem Hoppe Seyler       Date:  1995-03

10.  RNA annealing activities in HeLa nuclei.

Authors:  D S Portman; G Dreyfuss
Journal:  EMBO J       Date:  1994-01-01       Impact factor: 11.598

View more
  24 in total

1.  Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.

Authors:  M Amarzguioui; G Brede; E Babaie; M Grotli; B Sproat; H Prydz
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.

Authors:  B Bramlage; E Luzi; F Eckstein
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

3.  The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides.

Authors:  Rosel Kretschmer-Kazemi Far; Georg Sczakiel
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

4.  Promoter choice affects the potency of HIV-1 specific RNA interference.

Authors:  Daniel Boden; Oliver Pusch; Fredrick Lee; Lynne Tucker; Peter R Shank; Bharat Ramratnam
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

Review 5.  Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; R Thomas Taggart; Mark C Butler; Tiffany A Kolniak
Journal:  Vision Res       Date:  2007-10-31       Impact factor: 1.886

6.  Thermodynamic and kinetic characterization of antisense oligodeoxynucleotide binding to a structured mRNA.

Authors:  S Patrick Walton; Gregory N Stephanopoulos; Martin L Yarmush; Charles M Roth
Journal:  Biophys J       Date:  2002-01       Impact factor: 4.033

7.  Development and comparison of procedures for the selection of delta ribozyme cleavage sites within the hepatitis B virus.

Authors:  Lucien Junior Bergeron; Jean-Pierre Perreault
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

8.  A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.

Authors:  Edwin H Yau; Mark C Butler; Jack M Sullivan
Journal:  Exp Eye Res       Date:  2016-05-25       Impact factor: 3.467

9.  Thermodynamic criteria for high hit rate antisense oligonucleotide design.

Authors:  O V Matveeva; D H Mathews; A D Tsodikov; S A Shabalina; R F Gesteland; J F Atkins; S M Freier
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

10.  Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.

Authors:  Stephan Emmrich; Weiwei Wang; Katja John; Wenzhong Li; Brigitte M Pützer
Journal:  Mol Cancer       Date:  2009-08-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.